Education
About Us
Working with TipRanks
Follow Us
PainChek Ltd (AU:PCK)
ASX:PCK
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.19 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$43.89M
Enterprise ValueAU$40.18M
Total Cash (Recent Filing)AU$1.62M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumSustained top-line acceleration (~11% y/y) indicates increasing customer adoption and deeper penetration in existing accounts. For a subscription-based digital health product, steady revenue growth supports scale, predictable recurring cash flows and underpins future operating leverage.
Improving Gross MarginsImproving gross margin demonstrates better unit economics and potential pricing or cost efficiencies. If sustained, higher gross margins create room to invest in sales and R&D while narrowing the path to profitability as subscription revenue scales across care networks.
Debt-free Balance SheetZero debt reduces near-term insolvency risk and preserves financing optionality. For a cash-burning growth stage tech-health company, a debt-free position makes equity or strategic partner funding less costly and provides flexibility to support geographic expansion or product investment.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flow (~-6.8M) is a durable constraint: continuing cash burn forces frequent financing, dilutes shareholders or limits capital for sales and product development. Without improved cash conversion, growth is contingent on external funding.
Deep And Sustained UnprofitabilityExtremely negative net margins (~-228%) show that current revenues do not cover operating costs. This structural loss profile means profitability depends on large revenue scale or major cost restructuring, limiting durable free-cash-flow generation in the medium term.
Equity Erosion / Negative Shareholders' EquityTransition to negative equity signals accumulated losses and a weakened capital cushion. Negative equity can constrain strategic choices, make lenders cautious, and increase the likelihood of dilutive capital raises, impairing long-term financial flexibility and partner confidence.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.18 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$43.89M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Mar 04, 2026 which is in 11 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Aug 28, 2025. The company reported -AU$0.024 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.024.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.024 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.878%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$60.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-8647.54%
Trailing 12-Months
Asset Growth
-48.60%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---